Finanzas de Haemonetics Corp (HAE)HAEHaemonetics Corp

Haemonetics Corp (HAE) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Apheresis, accounting for 56.4% of total sales, equivalent to $191.32M. Another important revenue stream is MedSurg. Understanding this composition is critical for investors evaluating how HAE navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Haemonetics Corp maintains a gross margin of 56.98%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 20.68%, while the net margin is 9.73%. These profitability ratios, combined with a Return on Equity (ROE) of 11.20%, provide a clear picture of how effectively HAE converts its operational activities into shareholder value.

In the context of the broader market, HAE competes directly with industry leaders such as MMSI and GRAL. With a market capitalization of $5.40B, it holds a significant position in the sector. When comparing efficiency, HAE's gross margin of 56.98% stands against MMSI's 49.95% and GRAL's -28.12%. Such benchmarking helps identify whether Haemonetics Corp is trading at a premium or discount relative to its financial performance.

Haemonetics has shown strong financial performance with a gross margin of 56.98% and a net income of 33,010,000 USD in Q1 2027, despite a recent dip in Q4 2026.